UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 10-Q

|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.

For the quarterly period ended October 31, 2005

|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from ____________________ to ___________________

Commission File Number 0-944

POSSIS MEDICAL, INC.
--------------------
(exact name of registrant as specified in its charter)

Minnesota 41-0783184
- --------------------------------------------- -------------------------------
(State or other jurisdiction of incorporation I.R.S. Employer Identification
organization) No.)

9055 Evergreen Blvd NW Minneapolis MN 55433-8003
- ----------------------------------------- -------------------------------
(Address of principal executive offices) (Zip Code)

763-780-4555
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes _X_ No ___

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes _X_ No ___

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes ___ No _X__

The number of shares outstanding of the Registrant's Common Stock, $.40 par
value, as of November 30, 2005 was 17,260,137.

POSSIS MEDICAL, INC.

INDEX

PAGE
----

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements............................................................ 3

Consolidated Balance Sheets, October 31, 2005 and
July 31, 2005.................................................................. 3

Consolidated Statements of Income and Comprehensive Income for the three months
ended October 31, 2005 and 2004.................................................
4

Consolidated Statements of Cash Flows for the three months
ended October 31, 2005 and 2004................................................. 5

Notes to Consolidated Financial Statements....................................... 6

ITEM 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations............................................. 12

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk...................... 20

ITEM 4. Controls and Procedures.......................................................... 20

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings.............................................................. 20

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.................... 21

ITEM 6. Exhibits........................................................................ 21

SIGNATURES..................................................................... 22

PART 1 FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

POSSIS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

ASSETS October 31, 2005 July 31, 2005
---------------------- ----------------------

CURRENT ASSETS:
Cash and cash equivalents................................ $ 4,404,321 $ 5,257,244
Marketable securities.................................... 40,365,735 39,169,811
Trade receivables (less allowance for doubtful accounts
and returns of $677,000 and $669,000, respectively)..... 8,191,161 8,274,839
Inventories.............................................. 5,962,800 5,830,204
Prepaid expenses and other assets........................ 938,420 1,158,214
Deferred tax asset....................................... 1,042,000 1,042,000
-------------------- --------------------
Total current assets................................... 60,904,437 60,732,312

PROPERTY AND EQUIPMENT, net................................ 5,102,407 4,879,221
DEFERRED TAX ASSET......................................... 11,820,958 12,113,949
OTHER ASSET................................................ 440,425 425,914
-------------------- --------------------

TOTAL ASSETS............................................... $ 78,268,227 $ 78,151,396
==================== ====================

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
Trade accounts payable................................... $ 2,140,551 $ 1,355,402
Accrued salaries, wages, and commissions................. 2,225,055 3,212,525
Other liabilities........................................ 2,440,210 2,468,669
-------------------- --------------------
Total current liabilities............................. 6,805,816 7,036,596

OTHER LIABILITES........................................... 609,525 526,914

COMMITMENTS AND CONTINGENCIES..............................

SHAREHOLDERS' EQUITY:
Common stock-authorized, 100,000,000 shares of $0.40 par
value each; issued and outstanding, 17,259,137 and
17,326,487 shares, respectively......................... 6,903,655 6,930,595
Additional paid-in capital............................... 75,841,526 75,725,188
Unearned compensation.................................... (6,000) (15,000)
Accumulated other comprehensive loss..................... (339,000) (240,000)
Retained deficit......................................... (11,547,295) (11,812,897)
-------------------- --------------------
Total shareholders' equity.......................... 70,852,886 70,587,886
-------------------- --------------------

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 78,268,227 $ 78,151,396
==================== ====================

See notes to consolidated financial statements.

POSSIS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
FOR THE THREE MONTHS ENDED OCTOBER 31, 2005 AND 2004
(UNAUDITED)

2005 2004
----------------- -----------------

Product sales.......................................... $ 15,475,674 $ 17,501,988

Cost of sales and other expenses:
Cost of medical products............................ 4,230,155 4,304,339
Selling, general and administrative................. 8,393,727 7,556,583
Research and development............................ 2,509,293 2,437,704
----------------- -----------------

Cost of sales and other expenses................ 15,133,175 14,298,626
----------------- -----------------

Operating income....................................... 342,499 3,203,362
Interest income.................................... 403,449 286,432
(Loss) gain on sale of securities.................. (6,346) 18,081
----------------- -----------------

Income before income taxes............................. 739,602 3,507,875
Provision for income taxes............................. 474,000 1,315,000
----------------- -----------------

Net income............................................. 265,602 2,192,875

Other comprehensive (loss) income, net of tax:
Unrealized (loss) gain on securities................... (99,000) 125,000
----------------- -----------------
Comprehensive income................................... $ 166,602 $ 2,317,875
================= =================

Weighted average number of common of
Shares outstanding:
Basic.............................................. 17,315,847 18,080,940
Diluted............................................ 17,864,582 19,159,308

Net income per common share:
Basic.............................................. $ 0.02 $ 0.12
================= =================
Diluted............................................ $ 0.01 $ 0.11
================= =================

See notes to consolidated financial statements.

POSSIS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED OCTOBER 31, 2005 AND 2004
(UNAUDITED)

2005 2004
----------------- -----------------

OPERATING ACTIVITIES:
Net income....................................................... $ 265,602 $ 2,192,875
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation............................................... 615,442 562,211
Gain on asset disposal..................................... - (11,313)
Stock-based compensation expense........................... 749,054 9,000
Loss (gain) on sale of marketable securities............... 20,857 (17,140)
Deferred taxes............................................. 363,991 1,315,200
Decrease in trade receivables.............................. 83,678 1,346,821
Increase in inventories.................................... (281,332) (788,816)
Decrease in prepaid expenses and other assets.............. 205,283 267,041
Increase in trade accounts payable......................... 691,247 318,072
Decrease in accrued and other liabilities.................. (702,718) (1,205,718)
----------------- -----------------
Net cash provided by operating activities.................. 2,011,104 3,988,233

INVESTING ACTIVITIES:
Additions for property and equipment.......................... (595,990) (485,975)
Proceeds from sale of fixed assets............................ - 5,610
Proceeds from sale of marketable securities................... 6,577,704 16,164,230
Purchase of marketable securities............................. (7,955,485) (16,437,315)
----------------- -----------------
Net cash used in investing activities...................... (1,973,771) (753,450)

FINANCING ACTIVITIES:
Proceeds from issuance and exercise of options................ 211,858 286,216
Excess tax benefits from stock-based compensation............. (9,000) -
Repurchase of common stock................................. (1,093,114) (7,593,433)
----------------- -----------------
Net cash used in financing activities...................... (890,256) (7,307,217)
----------------- -----------------

(DECREASE) IN CASH AND CASH
EQUIVALENTS............................................ (852,923) (4,072,434)
CASH AND CASH EQUIVALENTS AT BEGINNING OF
QUARTER................................................ 5,257,244 8,411,784
----------------- -----------------
CASH AND CASH EQUIVALENTS AT END OF QUARTER...................... $ 4,404,321 $ 4,339,350
================= =================

SUPPLEMENTAL CASH FLOW DISCLOSURE:
Cash paid for income taxes.................................. $ 166,520 $ 132,500
Issuance of restricted stock................................ 230,600 -
Inventory transferred to property and equipment............. 7,736 39,360

See notes to consolidated financial statements.

POSSIS MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by
accounting principles generally accepted in the United States of America
for complete financial statements. In the opinion of management, all
adjustments (consisting of normal recurring accruals) considered necessary
for a fair presentation have been included. The accompanying consolidated
financial statements and notes should be read in conjunction with the
audited financial statements and accompanying notes thereto included in the
Company's 2005 Annual Report.

INTERIM FINANCIAL STATEMENTS

Operating results for the three months ended October 31, 2005 are not
necessarily indicative of the results that may be expected for the year
ending July 31, 2006.

2. EARNINGS PER SHARE

The following table presents a reconciliation of the numerators and
denominators of basic and diluted earnings per share:

Three Months Ended
October 31,
---------------------------------------------
2005 2004
--------------------- --------------------

Numerator:
Net income, basic and diluted $ 265,602 $ 2,192,875
===================== ====================

Denominator:
Weighted average common shares outstanding 17,315,847 18,080,940

Effect if potentially dilutive securities:
Stock options and other 548,735 1,078,368
--------------------- --------------------
Weighted average common shares outstanding,
assuming dilution
17,864,582 19,159,308
=================== ====================

Basic earnings per share $ 0.02 $ 0.12
Diluted earnings per share $ 0.01 $ 0.11

Potential dilutive securities include stock options, non-vested share
awards and shares issuable under our employee stock purchase plan (ESPP).

The computation of dilutive shares outstanding excluded options to purchase
1,910,000 and 403,000 shares of common stock for the three months ended
October 31, 2005 and 2004, respectively. These amounts were excluded
because the options' exercise prices were greater than the weighted average
closing market price of our common stock for the periods presented and
therefore, the effect would be antidilutive (i.e., including such options
would result in higher earnings per share.)

3. STOCK BASED-COMPENSATION

We have a stock-based compensation plan, which includes stock options,
non-vested share awards and an ESPP. Stock options issued prior to July 31,
2005 have a ten-year term. Stock options issued subsequent to July 31, 2005
have a five-year term. Outstanding stock options issued to employees
generally vest over a four-year period, however, on occasion the Company
has issued options that vest based upon achieving corporate objectives or
stock price performance. Outstanding stock options issued to directors vest
over the following periods, based on the basis for issuance: a) six months
- stock options in lieu of compensation for services rendered as directors,
b) four years - annual grants of stock options and c) stock price
performance with a seven-year cliff period - service award options.
Directors receive an annual non-vested share award that vests upon
continued employment (time based) of one year. Our ESPP permits employees
to purchase stock at 85% of the market price of our common stock at the
beginning or at the end of the annual purchase period, whichever is less.

Prior to August 1, 2005, we applied Accounting Principles Board Opinion No.
25, Accounting for Stock Issued to Employees, and related Interpretations
in accounting for these plans. No stock-based compensation expense was
recognized in our statements of income prior to fiscal 2006 for stock
option awards, as the exercise price was equal to the market price of our
stock on the date of grant. In addition, we did not recognize any
stock-based compensation expense for our ESPP as it is intended to be a
plan that qualifies under Section 423 of the Internal Revenue Code of 1986,
as amended. Finally, we recognized stock-based compensation expense for
non-vested share awards as discussed in Note 4, Common Stock, of the Notes
to Consolidated Financial Statements of our Annual Report on Form 10-K, for
the fiscal year ended July 31, 2005.

On August 1, 2005, we adopted the fair value recognition provisions of
Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004),
Share-Based Payment (123(R)), requiring us to recognize expense related to
the fair value of our stock-based compensation awards. We elected the
modified prospective transition method as permitted by SFAS No. 123(R).
Under this transition method, stock-based compensation expense for the
three months ended October 31, 2005, includes: (a) compensation expense for
all stock-based compensation awards granted prior to, but not yet vested as
of July 31, 2005, based on the grant date fair value estimated in
accordance with the original provisions of SFAS No. 123, Accounting for
Stock-Based Compensation; and (b) compensation expense for all stock-based
awards granted subsequent to July 31, 2005, based on the grant-date fair
value estimated in accordance with the provisions of SFAS No. 123(R). We
recognized compensation expense for stock options and non-vested share
awards, that are either market-based or time-based, on a straight-line
basis over the requisite service period of the award. Total stock-based
compensation expense included in our statement of income for the three
months ended October 31, 2005, was $822,000 ($702,000, net of tax). In
accordance with the modified prospective transition method of SFAS No.
123(R), financial results for prior periods have not been restated.

Prior to the adoption of SFAS No. 123(R), we reported all tax benefits
resulting from the exercise of stock options as operating cash flows in our
consolidated statements of cash flows. In accordance with the SFAS No.
123(R), for the three months ended October 31, 2005, we revised our
statement of cash flows presentation to report the excess tax benefits from
the exercise of stock options as financing cash flows. For the three months
ended October 31, 2005, $9,000 of excess tax benefits were reported as
financing cash flows rather than operating cash flows.

The following table illustrates the effect on net income and earnings per
share if we had applied the fair value recognition provisions of SFAS No.
123 to stock-based employee compensation during the three months ended
October 31, 2004.

2004
--------------

Net Income - as reported................................ $ 2,192,875
Deduct: Stock-based compensation expense
determined under fair value method for all
awards, net of tax.............................. (384,000)
--------------
Pro forma....................................... $ 1,608,875
==============
Earnings per share:
Basic - as reported..................................... $ 0.12
Deduct: Stock-based compensation expense
determined under fair value method for all
awards, net of tax.............................. (0.03)
--------------
Basic pro forma................................. $ 0.09
==============

Diluted - as reported $ 0.11
Deduct: Stock-based compensation expense
determined under fair value method for all
awards, net of tax.............................. (0.03)
--------------
Diluted - pro forma............................. $ 0.08
==============
Weighted average common shares outstanding
Basic........................................... 18,080,940
Diluted......................................... 19,159,308

For purposes of this pro forma disclosure, the value of the stock-based
compensation was amortized to expense on a straight-line basis over the
period it is vested or earned. Forfeitures were estimated based on
historical experiences.

The following table summarizes the stock option transactions for the three
months ended October 31, 2005:

Options Weighted- Average Weighted- Aggregate
Exercise Price Per Average Remaining Intrinsic
Share Contractual Term (in Value
years)

Outstanding on July 31, 2005 3,062,000 $11.78
Granted 414,000 $12.58
Exercised (20,000) $10.50
Forfeited/Canceled (135,000) $14.10
============== ===================== ====================
Outstanding on October 31, 2005
3,321,000 $11.78 5.95 $266,000
============== ===================== ==================== ===============
Exercisable on October 31, 2005
2,106,000 $10.53 5.17 $2,801,000
============== ===================== ==================== ===============

Note: At October 31, 2005, shares associated with our ESPP were not significant
and are excluded from the table above.

We estimated the fair values using the Black-Scholes option-pricing model
prior to August 1, 2005 and using the Actuarial Binomial option-pricing
model subsequent to July 31, 2005, modified for dividends and using the
following assumptions:

Three Months Ended
October 31,
--------------------------------------
2005 (1) 2004
---------------- -------------------

Risk-free rate (2)............................ 4.09% 4.1-4.5%

Expected dividend yield...................... 0% 0%
Expected stock price volatility (3)........... 37.82% 54-64%
Expected life of stock options (4)............ 4.14 years 10 years
Fair value per option........................ $4.38-$5.60 $11.86-19.88

1. Forfeitures are estimated based on historical experience.
2. 2005 - Based on the U.S. Treasury interest rates whose term is
consistent with the expected life of our stock options. 2004 - Based
on the ten-year U.S. Treasury constant maturity interest rate.
3. In 2005 we used an outside valuation advisor to assist us in more
accurately projecting expected stock price volatility. We used
historical market price data.
4. We estimate the expected life of stock options based upon historical
experience.

Net cash proceeds from the exercise of stock options were $212,000 and
$286,000 for the three months October 31, 2005 and 2004, respectively.

The actual income tax benefit realized from stock option exercises totaled
$9,000 and $235,000 for the three months October 31, 2005 and 2004,
respectively.

Non-Vested Share Awards

The fair value of non-vested market-based and time-based share awards is
determined based on generally accepted valuation techniques and the closing
market price of our stock on the date of grant. A summary of the status of
our non-vested market-based and time-based share awards as of October 31,
2005 and changes during the three-month period ended October 31, 2005, is
as follows:

Market-Based and Time-Based Share Awards Shares Fair Value
---------------------------------------- ------ ----------
Outstanding at July 31, 2005 2,754 $11.70
Granted 18,353 12.57
Vested (12,064) 13.03
Forfeited/Canceled (6,289) 13.03
Outstanding at October 31, 2005 2,754 $11.86
========== ==========

No time-based share awards vested during the three months ended October 31,
2005. As of October 31, 2005, there was $6,000 of unrecognized compensation
expense related to non-vested time-based share awards that is expected to
be recognized over the next two months.

4. ACCOUNTING PRONOUNCEMENTS

In November 2003 and March 2004, the Emerging Issues Task Force (EITF)
reached a consensus on EITF Issue No. 03-1, "The Meaning of
Other-Than-Temporary Impairment and Its Application to Certain
Investments." The consensus reached requires companies to apply new
guidance for evaluating whether an investment is other-than-temporarily
impaired and also requires quantitative and qualitative disclosure of debt
and equity securities, classified as available-for-sale or
held-to-maturity, that are determined to be only temporarily impaired at
the balance sheet date. The Company incorporated the required disclosures
for investments accounted for under SFAS No. 115, "Accounting for Certain
Investments in Debt and Equity Securities," as required in the fourth
quarter of fiscal year 2004. In September 2004, the consensus was
indefinitely delayed as it relates to the measurement and recognition of

impairment losses for all securities in the scope of paragraphs 10-20 of
EITF 03-1. The disclosures prescribed by EITF No. 03-1 and guidance related
to impairment measurement prior to the issuance of this consensus continue
to remain in effect. Adoption is not expected to have a material impact on
the Company's consolidated earnings, financial position or cash flows.

In April 2005, the FASB issued FIN No. 47 to clarify the scope and timing
of liability recognition for conditional asset retirement obligations
pursuant to SFAS No. 143 - "Accounting for Asset Retirement Obligations".
The interpretation requires that a liability be recorded for the fair value
of an asset retirement obligation, if the fair value is estimable, even
when the obligation is dependent on a future event. FIN No. 47 further
clarified that uncertainty surrounding the timing and method of settlement
of the obligation should be factored into the measurement of the
conditional asset retirement obligation rather than affect whether a
liability should be recognized. Implementation is required to be effective
no later than the end of fiscal years ending after Dec. 15, 2005.
Additionally, FIN No. 47 will permit but not require restatement of interim
financial information during any period of adoption. Both recognition of a
cumulative change in accounting and disclosure of the liability on a pro
forma basis are required for transition purposes. The Company is evaluating
the impact of FIN No. 47, however, it is not expected to have a material
impact on results of operations or financial position.

5. MARKETABLE SECURITIES

During the quarter ended October 31, 2005, we invested excess cash and cash
equivalents in a professionally managed portfolio of marketable securities.
All securities in this portfolio are classified as available-for-sale and
consist primarily of U.S. government securities and corporate bonds. These
investments are reported at fair value. The unrealized loss, net of taxes,
on these investments of approximately $99,000 for the three months ended
October 31, 2005 is included within other comprehensive loss. The
unrealized gain, net of taxes, on these investments, of approximately
$125,000 for the three months ended October 31, 2004 is included within
other comprehensive gain. The net unrealized loss included in shareholders'
equity as of October 31, 2005 and 2004 was $339,000 and $11,000, net of
tax.

6. INVENTORIES

Inventories are stated at the lower of cost (on the first-in, first-out
basis) or market. Inventory balances were as follows:

Oct. 31, 2005 July 31, 2005
-------------------- ------------------------

Finished goods.......................... $ 2,213,580 $ 2,149,599
Work-in-process......................... 1,110,832 1,206,364
Raw materials........................... 2,638,388 2,474,241
-------------------- ------------------------
$ 5,962,800 $ 5,830,204
==================== ========================

7. PROPERTY AND EQUIPMENT

Property is carried at cost and depreciated using the straight-line method
over the estimated useful lives of the various assets. Property and
equipment balances and corresponding lives were as follows:

Oct.31, 2005 July 31, 2005 Life
------------------- --------------------- -------------------

Leasehold improvements........................ $ 2,450,311 $ 2,295,999 7-10 years
Equipment..................................... 10,641,029 10,329,650 3 to 10 years
Assets in construction........................ 447,468 222,467 N/A
------------------- ---------------------
13,538,808 $12,848,116
Less accumulated depreciation................. (8,436,401) (7,968,895)
------------------- ---------------------

Property and equipment - net.................. $ 5,102,407 $ 4,879,221
=================== =====================

8. SEGMENT AND GEOGRAPHIC INFORMATION AND CONCENTRATION OF CREDIT RISK

Our operations are in one business segment: the design, manufacture and
distribution of cardiovascular medical devices. We evaluate revenue
performance based on the worldwide revenues of each major product line and
profitability based on an enterprise-wide basis due to shared
infrastructures to make operating and strategic decisions.

Total revenues from sales in the United States and outside the United
States are as follows:

Three Months Ended
October 31,
2005 2004
-------------------- -------------------

United States................... $ 15,050,856 $17,198,858
Non-United States............... 424,818 303,130
-------------------- -------------------
Total Revenues.................. $ 15,475,674 $17,501,988
==================== ===================

9. NET INCOME PER COMMON SHARE

Basic income per common share is computed by dividing net income for the
period by the weighted average number of common shares outstanding during
the period. Diluted income per share is computed using the treasury stock
method by dividing net income by the weighted average number of common
shares plus the dilutive effect of outstanding stock options, and shares
issuable under the employee stock purchase plan.

10. COMMON STOCK

During the three months ended October 31, 2005, stock options for the
purchase of 20,186 shares of the Company's common stock were exercised at
prices between $6.38 and $12.44 per share resulting in proceeds of
$212,000. During the three months ended October 31, 2004, stock options for
the purchase of 56,887 shares of the Company's common stock were exercised
at prices between $3.94 and $16.66 per share resulting in proceeds of
$285,000.

There were no shares issued in connection with our employee stock purchase
plan during the three months ended October 31, 2005. During the three
months ended October 31, 2004, we issued 81 shares in connection with our
employee stock purchase plan.

On August 29, 2005, we issued 18,353 shares of restricted stock to
executives of the Company as part of the fiscal 2005 management incentive
program. The fair market value of the restricted stock was $230,600. The
restricted stock vests at the time our stock price closes at $13.00 or
greater. On August 31, 2005 the Company's stock price closed at $13.03. The
$230,600 was expensed in fiscal 2005 as compensation expense. We cancelled
6,289 shares of restricted stock due to the executives electing to receive
fewer shares in lieu of paying the withholding taxes.

During the three months ended October 31, 2005, we repurchased 99,600
shares in the public market at prices between $10.93 and $11.06 per share
for $1,093,000. During the three months ended October 31, 2004, we
repurchased 503,000 shares in the public market at stock prices between
$10.66 and $18.34 per share for $7,593,000.

11. ACCRUED WARRANTY COSTS

We estimate the amount of warranty claims on sold product that may be
incurred based on current and historical data. The actual warranty expense
could differ from the estimates made by the Company based on product
performance. The following table presents the changes in our product
warranty liability:

Accrued warranty costs at July 31, 2005 $ 146,500
Payments made for warranty costs............................ (103,500)
Provision for product costs................................
103,500
-----------------
Accrued warranty costs at October 31, 2005................. $ 146,500
=================

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Our Business

Possis Medical Inc. develops, manufactures, and markets pioneering medical
devices for mechanical thrombectomy in native coronary arteries and coronary
bypass grafts, leg arteries and in kidney dialysis access grafts. Our primary
product, the AngioJet(R) RheolyticTM Thrombectomy System (AngioJet System) uses
miniaturized waterjet technology, which enables interventional cardiologists,
interventional radiologists, vascular surgeons, and other specialists to
rapidly, safely and effectively remove blood clots throughout the body.

The proprietary AngioJet System consists of a drive unit (capital equipment), a
disposable pump set that delivers pressurized saline to a catheter, and a
variety of disposable catheters that are specifically designed for particular
clinical indications. The AngioJet coronary catheter is a Class III medical
device and is marketed in the U.S. under an approved PMA. The AngioJet av-access
and peripheral arterial catheters are Class II devices are marketed in the U.S.
under cleared 510(k) submissions.

We expect U.S. AngioJet System sales to grow primarily through obtaining
additional FDA approved product uses, introduction of new catheter models for
existing indications, introduction of AngioJet System-related products, more
face-time selling to existing accounts, peer-to-peer selling, and the
publication of clinical performance and cost-effectiveness data.

Critical Accounting Policies

Our consolidated financial statements include accounts of Possis Medical, Inc.
and all wholly-owned subsidiaries. The preparation of financial statements in
conformity with accounting principles generally accepted in the United States of
America requires us to make estimates and assumptions in certain circumstances
that affect amounts reported in the accompanying consolidated financial
statements and related footnotes. In preparing these financial statements, we
have made our best estimates and applied our best judgment of certain amounts
included in the financial statements, giving due consideration to materiality.
Our most critical accounting policies are those described below. Application of
these accounting policies involves the exercise of judgment and use of
assumptions as to future uncertainties and, as a result, actual results could
differ from these estimates.

Revenue Recognition

Revenues associated with AngioJet drive units that are maintained at customer
locations are recognized, and title and risk of loss on those drive units is
transferred to the customer when we receive a valid purchase order from the
customer. Revenue is not recognized for AngioJet drive units that are maintained
at customer locations as evaluation drive units. We do not lease AngioJet drive
units. Revenues associated with products that are shipped to customers from our
facilities are recognized, and title and risk of loss are transferred to the
customer, when a valid purchase order is received and the products are received
at the customer's location. Provisions for returns are recorded in the same

period the related revenues are recognized. Revenue recognition for drive unit
extended warranties is amortized on a straight-line basis over the life of the
warranty period that is generally twelve months.

Allowance for Returns

Trade receivable, are reduced by an allowance for items that may be returned in
the future. The allowance requires us to make estimates at the time the account
receivable is recorded concerning the likelihood of returns. The estimate is
based upon our historical product return experience, customer complaint rates,
information received from our customers and other assumptions that we believe
are reasonable under the circumstances. We review, on a quarterly basis, the
actual returns for the previous quarter and evaluate the adequacy of the
allowance for future returns. Although we believe the amount of the allowance
for returns is appropriate, actual returns incurred could differ from our
original estimate, requiring adjustments to the allowance.

Allowance for Doubtful Accounts

Substantially all of our trade receivables are due from health care facilities
located in the United States. The estimated allowance for doubtful accounts is
based upon the age of the outstanding receivables and the payment history and
creditworthiness of each customer. We evaluate the adequacy of the allowance for
doubtful accounts on a quarterly basis. Although we believe the amount of the
allowance for doubtful accounts is appropriate, nonpayment of accounts could
differ from our original estimate, requiring adjustments to the allowance.

Inventories

We value inventories at the lower of cost or market. In order to determine the
market value of inventory, on a quarterly basis, we assess the inventory
quantities on hand to estimate future usage and sales and, if necessary, set up
an obsolescence reserve for inventory deemed excess or obsolete to estimate
market value. Although we believe the amount of the reserve for inventory
obsolescence is appropriate, the amount of our inventory that becomes obsolete
may differ from our original estimate, requiring adjustments to the reserve.

Warranty Reserve

We provide a one-year limited warranty on our AngioJet System drive unit and a
limited warranty on AngioJet System disposable products. We establish a warranty
reserve at the time products are sold that is based upon historical frequency of
claims relating to our products and the cost to replace disposable products and
to repair drive units under warranty. We evaluate the adequacy of the warranty
reserve on a quarterly basis. Although we believe the amount of the warranty
reserve is appropriate, given our historical experience, if actual claims
incurred differ from the original estimate, we would be required to adjust the
reserve.

Non-GAAP (General Accepted Accounting Principles) Disclosures

In our Management's Discussion and Analysis, and Notes to Consolidated Financial
Statements, the Company makes reference to non-GAAP financial measures - the
effect on net income, net income after tax and net income per share resulting
from compensation charges under SFAS 123 (R), and other non-GAAP line items from
the Consolidated Statements of Income and Comprehensive Income, including cost
of medical products, operating expenses (including selling, general and
administrative, and research and development), and provision for income taxes.
These measures are not in accordance with, or an alternative for, generally
accepted accounting principles and may be different from non-GAAP measures used
by other companies. Possis believes that the presentation of non-GAAP net
income, non-GAAP net income per share data, and other non-GAAP line items from
the Consolidated Statements of Income and Comprehensive Income, when shown in
conjunction with the corresponding GAAP measures, provides useful information to
management and investors regarding financial and business trends relating to its
financial condition and results of operations. Possis further believes that
where the adjustments used in calculating non-GAAP net income and non-GAAP net
income per share are based on specific identified charges that impact different
line items in the statements of income (including cost of medical products,
selling, general and administrative and research and development expense), that

it is useful to investors to know how these specific line items in the
statements of income are affected by these adjustments. In particular, as Possis
begins to apply SFAS 123(R), it believes that it is useful to investors to
understand how the expenses associated with the application of SFAS 123(R) are
reflected in its Consolidated Statements of Income and Comprehensive Income.

Financial Reporting Changes

Stock-Based Compensation

On December 16, 2004, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004),
Share-Based Payment (123(R)), effective for a company's first fiscal year
beginning after June 15, 2005, SFAS No. 123(R) supercedes Accounting Principles
Board Opinion No. 25, Accounting for Stock Issued to Employees. SFAS No. 123(R)
requires all share-based compensation, including grants of stock options, to be
recognized in the consolidated statements of earnings.

During the first quarter of fiscal 2006, we adopted SFAS No. 123(R), and elected
the modified prospective transition method. This method permits us to apply the
new requirements on a prospective basis. Our net income for the three months
ended October 31, 2005 included stock-based compensation expense of $822,000
($702,000 after tax, or $0.04 per diluted share). Our cost of medical products
for the three months ended October 31, 2005 included stock-based compensation of
$102,000. Our selling, general and administrative expense for the three months
ended October 31, 2005 included stock-based compensation of $531,000. Our
research and development expense for the three months ended October 31, 2005
included stock-based compensation of $189,000. For additional information on our
adoption of SFAS No. 123(R), see Note 3, Stock-Based Compensation of the Notes
to Consolidate Financial Statements in this Quarterly Report on Form 10-Q.

Results of Operations

Three Month Periods Ended October 31, 2005 and 2004

Summary

Total product sales for the three months ended October 31, 2005 decreased
$2,026,000, or 12%, to $15,476,000 compared to $17,502,000 for the comparable
period in fiscal 2005.

We recorded net income for the quarter ended October 31, 2005 of $266,000, or
$0.01 per diluted share, compared to net income of $2,193,000, or $0.11 per
diluted share, in the comparable quarter in fiscal 2005. Net income for the
quarter ended October 31, 2005, reflects the impact of adopting SFAS No.123(R),
which resulted in stock-based compensation expense of $822,000, ($702,000 after
tax, or $0.04 per diluted share).

The following table compares the Statement of Income as reported with the
pro-forma non-GAAP Statement of Income for the three months ended October 31,
2005, eliminating the impact of SFAS 123(R) on the Statement of Income.

Pro-forma
Non-GAAP
SFAS 123(R) Excluding
As Reported Adjustments SFAS 123(R)
--------------- --------------- ---------------

Product sales $ 15,475,674 $ - $ 15,475,674

Cost of sales and other expenses:
Cost of medical products 4,230,155 102,000 4,128,155
Selling, general and administrative 8,393,727 531,000 7,862,727
Research and development 2,509,293 189,000 2,320,293
-------------- -------------- --------------
Cost of sales and other expenses 15,133,175 822,000 14,311,175
Operating income 342,499 (822,000) 1,164,499
Interest income 403,449 403,449
(Loss) gain on sale of securities (6,346) (6,346)
-------------- --------------- --------------
Income before income taxes 739,602 (822,000) 1,561,602
Provision for income taxes (474,000) 120,000 (594,000)
-------------- -------------- --------------
Net income 265,602 (702,000) 967,602

Other comprehensive loss net of tax:
Unrealized loss on securities (99,000) - (99,000)
-------------- -------------- --------------
Comprehensive income $ 166,602 $ (702,000) $ 868,602
============== ============== ==============

Net income per common share
Basic $ 0.02 $ 0.04 $ 0.06
============== ============== ==============
Diluted $ 0.01 $ 0.04 $ 0.05
============== ============== ==============

Operating Expenses

The following tables compare dollars (in thousands) and percentage changes in
the Statements of Income Between 2005 and 2004.

Pro-forma Non-GAAP
As Reported* Excluding SFAS 123(R)
-----------------------------------------------------------------------------------------------
Increase Increase
October 31, (Decrease) October 31, (Decrease)
--------------------------- -----------------------
2005 2004 Dollars Percent 2005 2004 Dollars Percent
------------ ------------------------------------ ---------- ------------------------------

Product sales $ 15,476 $ 17,502 $ (2,026) (11.6%) $ 15,476 $ 17,502 $ (2,026) (11.6%)

Operating expenses
Cost of medical products 4,230 4,304 (74) (1.7%) 4,128 4,304 (176) (4.1%)
Selling, general and
administrative 8,394 7,557 837 11.1% 7,863 7,557 306 4.1%
Research and
development 2,509 2,438 71 2.9% 2,320 2,438 (118) (4.8%)
Total 15,133 14,299 834 5.8% 14,311 14,299 12 .1%

Operating income 343 3,203 (2,860) (89.3%) 1,165 3,203 (2,038) (63.6%)

Other income 397 305 92 30.2% 397 305 92 30.2%

Income before income
taxes 740 3,508 (2,768) (78.9%) 1,562 3,508 (1,946) (55.5%)
Income taxes provision (474) (1,315) 841 (64.0%) (594) (1,315) 721 (54.8%)
Net income $ 266 $ 2,193 $ (1,927) (87.9%) $ 968 $ 2,193 $ (1,125) (55.9%)

*Note: Net income for the first quarter of fiscal 2006 includes stock-based
compensation expense of $702,000, net of tax, due to the implementation of FAS
123(R). Net income for the first quarter of fiscal 2005 did not include
stock-based compensation under SFAS 123.

The following tables show the Statement of Income as a percentage of product
sales for the three months ended October 31, 2005 and 2004.

Pro-forma Non-GAAP excluding
As Reported SFAS 123(R)
----------- -----------
2005 2004 2005 2004
---- ---- ---- ----

Product sales 100.0% 100.0% 100.0% 100.0%

Operating expenses
Cost of medical products 27.3% 24.6% 26.7% 24.6%
Selling, general and administrative 54.2% 43.2% 50.8% 43.2%
Research and development 16.2% 13.9% 15.0% 13.9%
Total 97.8% 81.7% 92.5% 81.7%

Operating income 2.2% 18.3% 7.5% 18.3%
Other income 2.6% 1.7% 2.6% 1.7%
Income before income taxes 4.8% 20.0% 10.1% 20.0%
Income taxes provision -3.1% -7.5% -3.8% -7.5%
Net income 1.7% 12.5% 6.3% 12.5%

Revenue

U.S. product sales for the three months ended October 31, 2005 decreased 12% to
$15,051,000 from $17,199,000 for the same period in 2005. The main factors in
the revenue decrease during fiscal 2005 was higher than expected sales force
turnover, increased competition, and continuing controversy concerning the role
of thrombectomy and embolic protection in treating coronary STEMI (ST segment
elevation myocardial infarction) patients.

As of October 31, 2005, we had a total of 1,560 domestic drive units in the
field, compared to 1,371 drive units at October 31, 2004, and 1,509 units as of
July 31, 2005. During the three month period ended October 31, 2005, our
catheter sales decreased approximately 7% to approximately 11,900 catheters
versus approximately 12,800 catheters in the same prior year period. The average
catheter utilization rate per installed domestic drive unit was 7.5 in the first
quarter of fiscal 2006 compared to 9.3 in the same prior year period, and
compared to a rate of 8.2 in the fourth quarter of fiscal 2005. We sold 42
domestic drive units during the three months ended October 31, 2005, compared to
49 drive units in the same period in the prior year and compared to 40 drive
units in the fourth quarter of fiscal 2005.

Foreign product sales for the three months ended October 31, 2005 and 2004 were
$425,000 and $303,000, respectively.

Cost of Medical Products

Cost of medical products decreased $74,000 to $4,230,000 in the three month
period ended October 31, 2005 over the same period in the previous year. The
decrease was primarily due to the reduction in AngioJet System product unit
sales offset by higher production overhead on lower units produced combined with
an increase in overhead costs. Cost of medical products for the three months
ended October 31, 2005 reflect the impact of adopting SFAS No. 123(R), which
resulted in increased stock-based compensation expense of $102,000.

Gross profit decreased by $1,952,000 to $11,246,000, or 72.7% of product sales,
for the three months ended October 31, 2005, from $13,198,000 or 75.4% of
product sales in the same period in the previous year. The decrease in the gross
profit margin was primarily due to lower revenue and to a shift to products
carrying a lower gross profit margin compared to the same period in the previous
year.

Selling, General and Administrative Expense

Selling, general and administrative expense increased $837,000 to $8,394,000 for
the three months ended October 31, 2005 compared to the same periods in the
previous year. The primary factor in the expense increase for the three months
ended October 31, 2005 was the adoption of SFAS No. 123(R). The impact of the
stock-based compensation expense relating to the implementation of SFAS No.
123(R) was $531,000. Other factors contributing to the expense increase were
medical insurance costs, commissions, and incentives. These expenses increases
were partially offset by a reduction in expenses associated with marketing
clinical trials.

Research and Development Expense

Research and development expense increased $71,000 to $2,509,000, in the three
months ended October 31, 2005, when compared to the same period in the prior
year. The increase was largely due to the impact of adopting SFAS No. 123(R)
which resulted in increased stock-based compensation of $189,000.

We believe that research and development expenses for AngioJet System
applications and related products will decrease in fiscal 2006 over fiscal 2005
levels.

Interest Income

Interest income increased $117,000 in the three months ended October 31, 2005 to
$403,000, when compared to the same period in the prior year. The increase was
due to the recent interest rate increases and an increase in the amount of cash
available for investments. Excess cash is invested in a professionally managed
portfolio of marketable securities. We expect interest income to increase in
fiscal 2006 as compared to fiscal 2005 due to positive operating cash flows and
current interest rates.

(Loss) Gain On Sale of Securities

Loss on sales of securities was $6,000 for the three months ended October 31,
2005. Gain on sales of securities was $18,000 for the three months ended October
31, 2004. The losses in fiscal 2005 were due to interest rate increases that
reduced the fair market value of the investments in marketable securities.
Future gain (loss) on sale of securities is dependent on interest rate
fluctuations.

Provision For Income Taxes

Our effective tax rate in the three month period ending October 31, 2005, was 64
percent. On a non-GAAP basis (excluding the impact of SFAS 123 (R)) the
effective tax rate was 38 percent in the current period. The increase in the
GAAP effective tax rate in the current quarter is attributable to how Incentive
Stock Options (or ISO's) are treated under SFAS 123 (R). There is no tax benefit
recognized for ISO expense under SFAS 123(R) until there is an exercise and
associated disqualifying disposition resulting in an actual tax benefit for the
Company. Non-Qualified stock options are fully tax effected under SFAS 123 (R)
as the value is expensed over the vesting period. Approximately 70 percent of
our outstanding options at this time are ISO's so the impact on Possis Medical
is significant. This new ISO tax treatment under 123 (R) reduced earnings by
$0.01 per share in the current quarter.

We became profitable in the third quarter of fiscal 2001 and has maintained
profitability since. In fiscal 2005 and 2004, we increased our deferred tax
asset by an additional $466,000 and $2,578,000, respectively. These increases
were related to tax benefits from disqualified stock options that are recorded
directly in the Consolidated Statement of Changes in Shareholders' Equity.
Management believes the remaining valuation allowance of $690,000 is necessary
as it is more likely than not that $690,000 of the deferred tax asset will not
be realizable due to the expiration of research and development tax credits.

Liquidity and Capital Resources

Our cash, cash equivalents and marketable securities totaled approximately
$44,770,000 at October 31, 2005 versus $44,427,000 at July 31, 2005.

During the three months ended October 31, 2005, we generated $2,011,000 of cash
from operating activities, which resulted primarily from $266,000 net income,
depreciation of $615,000, a decrease in deferred tax assets of $364,000, a
decrease in accounts receivable of $84,000, a decrease in prepaid expenses and
other assets of $205,000 and an increase in accounts payable of $691,000. These
sources of cash from operations were partially offset by cash used to fund an
increase in inventories of $281,000, and a decrease in accrued liabilities of
$703,000. We depreciate company-owned drive units at customer locations, as well
as property and equipment. The decrease in the deferred tax asset was due to the
utilization of the net operating loss carry-forwards to offset current taxes
payable. The increase in accounts payable was due to the timing of payments.
Inventory increased as new catheter models were released during the first
quarter. The decreases in accrued liabilities were due to the timing of
payments. This decrease included the payment of fiscal 2005 corporate incentives
in September 2005.

Cash used in investing activities was $1,974,000 including the net purchase of
marketable securities of $1,378,000 and the purchase of $596,000 of property and
equipment.

Net cash used in financing activities was $890,000, which resulted from the
repurchase of 99,600 shares of our stock in open market transactions for
$1,093,000, offset by the cash received in connection with the exercise of stock
options of $212,000.

We expect our cash on hand and funds from operations to be sufficient to cover
both short-term and long-term operating requirements of its current AngioJet
business and the repurchase of its common stock as authorized by the Board of
Directors.

Off-Balance Sheet Obligations

The Company does not have any material off-balance-sheet arrangements.

Outlook

We expect overall revenue from the AngioJet System, primarily in the United
States, will be in the range of $66 million to $70 million in fiscal 2006. Gross
margin as a percent of sales for fiscal 2006 is expected to be in the low to
mid-seventies. We expect selling, general and administrative expenses to
increase from fiscal 2005 levels. Research and development expense levels are
dependent upon the continuing development of its current products and investment
in the development of new AngioJet System thrombectomy applications and related
products, including clinical trials. Including the impact of stock-based
compensation expense, we anticipates net income per diluted share of $0.16 to
$0.24 for fiscal 2006. The Company anticipates second-quarter revenue to be
approximately $15.7 to $16.1 million and net income in the range of $0.01 to
$0.03 per diluted share. The impact of expensing stock-based compensation per
SFAS 123(R) is anticipated to be approximately $0.05 per diluted share for the
second quarter and approximately $0.18 per diluted share for fiscal year 2006.

Forward-Looking Statements

Certain statements made in Management's Discussion and Analysis of Financial
Condition and Results of Operations and elsewhere in this Form 10-Q, and
particularly the statements made in the section captioned "Outlook," are
"forward-looking statements" as defined in the Private Securities Litigation
Reform Act of 1995. These forward-looking statements relate to among other
things, financial projections such as anticipated gross margins, overall
revenue, expected expense levels, anticipated revenue increases and investment
levels.

Forward-looking statements in this 10-Q are based on the Company's current
expectations and assumptions and entail various risks and uncertainties that
could cause actual results to differ materially from those expressed in such
forward-looking statements. Factors that could affect the realization of
forward-looking statements include:

o changes in clinical and market acceptance of our products;
o changes in the health care industry generally, such as restrictions
imposed on sales time at interventional labs; consolidation of
industry participants, cost containment and trends toward managed
care;
o changes in supplier requirements by group purchasing organizations;
o unanticipated costs or other difficulties and uncertainties associated
with lengthy and costly new product development and regulatory
clearance processes;
o changes in governmental laws and regulations;
o changes in reimbursement;
o the development of new competitive products such as inexpensive
aspiration devices, combined aspiration/occlusion products and
compounds that may make our products obsolete;
o sudden restrictions in supply of key materials;
o the effectiveness of our sales and marketing efforts in
re-establishing coronary product usage,
o our ability to effectively manage new product development timelines,
o our ability to effectively manage marketing and investigational device
exempt clinical trials

o our ability to generate suitable clinical registry data to support
growing use of the AngioJet in coronary applications,
o our the ability to obtain additional regulatory approvals on a timely
basis;
o our ability to obtain regulatory clearance in new foreign markets and
o our ability to retain and motivate skilled employees, especially for
sales positions.

Undue reliance should not be placed on forward-looking statements, which speak
only as of the date made. Any or all forward-looking statements in this report
and in any other public statements we make may turn out to be inaccurate or
false. They can be affected by inaccurate assumptions we might make or by known
or unknown risks and uncertainties. Except as required by federal securities
laws, we undertake no obligation to update any forward-looking statement. A
discussion of these and other factors that could impact our future results are
set forth in the risk factors included in the Company's Form 10-K for the year
ended July 31, 2005 as filed with the Securities and Exchange Commission.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We invest our excess cash in a professionally managed, institutional fixed
income portfolio of short duration. The market risk on a diversified portfolio
of relatively short duration is minimal, while enhancing returns above money
market levels.

The product sales for the Company's foreign subsidiary are in U.S. Dollars
("USD") except for product sales in Germany, which are in euro's. The German
product sales were minimal during the first quarter. The Company has a foreign
bank account in which the German product sales receipts are deposited and
immediately transferred to the operating bank account in the United States. The
balance in the German bank account was zero as of October 31, 2005.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures
- ------------------------------------------------

Under the supervision and with the participation of our management, including
our Chief Executive Officer and Chief Financial Officer, we evaluated the
effectiveness of the design and operation of our disclosure controls and
procedures (as defined in Rule 13a-15(e) under the Exchange Act. Based upon that
evaluation, the Chief Executive Officer and Chief Financial Officer concluded
that, as of the end of the period covered by this report, our disclosure
controls and procedures were effective in ensuring that information required to
be disclosed by us in the reports we file or submit under the Exchange Act is
recorded, processed, summarized and reported, within the time periods specified
in applicable rules and forms and that such information is accumulated and
communicated to our management, including our Chief Executive Officer and Chief
Financial Officer, in a manner that allows timely decisions regarding required
disclosure.

Changes in internal control over financial reporting
- ----------------------------------------------------

During the fiscal quarter ended October 31, 2005, there has been no change in
our internal control over financial reporting (as defined in Rule 13a-15(f)
under the Exchange Act) that has materially affected, or is likely to materially
affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1 LEGAL PROCEEDINGS

We were served with a shareholder lawsuit that was filed with the Minnesota
Federal District Court on June 3, 2005, alleging that Possis Medical, Inc. and
named individual officers violated federal securities laws during a period
beginning in 2002. The Complaint seeks class action status and unspecified
damages. We believe that the allegations of the lawsuit are without merit and
are contesting the lawsuit vigorously. We do not believe that the amount of any
potential liability associated with these matters can be estimated at this time,

but an unfavorable resolution of these matters could have a material adverse
effect on our results of operations, financial condition or cash flows.

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Company Repurchases of Equity Securities

- --------------------------------- ---------------------- ----------------------- -------------------- --------------------------

(d) Maximum Number (or
Approximate Dollar
(c) Total Number of Value) of Shares that
Shares Purchased as Part May Yet Be Purchased
(a) Total Number of (b) Average Price of Publicly Announced Under the Plans or
Period Shares Purchased Paid per Share Plans or Programs Programs
- --------------------------------- ---------------------- ----------------------- -------------------- --------------------------
August 1, 2005 to - - - -
August 31, 2005
- --------------------------------- ---------------------- ----------------------- -------------------- --------------------------
September 1, 2005 to September
30, 2005 89,600 $10.97 89,600
- --------------------------------- ---------------------- ----------------------- -------------------- --------------------------
October 1, 2005 to October 31,
2005 10,000 $11.06 10,000 $12,067,000
- --------------------------------- ---------------------- ----------------------- -------------------- --------------------------
Total 99,600 $10.98 99,600 $12,067,000
- --------------------------------- ---------------------- ----------------------- -------------------- --------------------------

The Company repurchased an aggregate of 99,600 shares of its common stock
pursuant to the repurchase program that it publicly announced on February
23, 2005 providing for the repurchase of shares having a value of up to
$15,000,000 through December 2006. The shares were purchased in open market
transactions.

ITEM 6. EXHIBITS

Exhibits

Certain of the following exhibits are incorporated by reference from prior
filings. The form with which each exhibit was filed and the date of filing are
indicated below.

Exhibit Description
----------------- ---------------------------------------------------------

31.1 Certification of the Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of the Chief Executive Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of the Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

POSSIS MEDICAL, INC.

DATE: December 9, 2005 By: /s/ Robert G. Dutcher
------------------------------
ROBERT G. DUTCHER
Chairman, President and Chief
Executive Officer

DATE: December 9, 2005 By: /s/ Jules L. Fisher
------------------------------
JULES L. FISHER
Vice President of Finance and
Chief Financial Officer

EXHIBIT INDEX

Certain of the following exhibits are incorporated by reference from prior
filings. The form with which each exhibit was filed and the date of filing are
indicated below.

Exhibit Description
----------------- ---------------------------------------------------------